Prometheus Biosciences Probability of Future Stock Price Finishing Over 199.92

RXDXDelisted Stock  USD 199.92  0.24  0.12%   
Prometheus Biosciences' future price is the expected price of Prometheus Biosciences instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Prometheus Biosciences performance during a given time horizon utilizing its historical volatility. Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment.
  
Please specify Prometheus Biosciences' target price for which you would like Prometheus Biosciences odds to be computed.

Prometheus Biosciences Target Price Odds to finish over 199.92

The tendency of Prometheus Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 199.92 90 days 199.92 
about 20.48
Based on a normal probability distribution, the odds of Prometheus Biosciences to move above the current price in 90 days from now is about 20.48 (This Prometheus Biosciences probability density function shows the probability of Prometheus Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the stock has the beta coefficient of 2.34 indicating as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Prometheus Biosciences will likely underperform. Additionally Prometheus Biosciences has an alpha of 0.8296, implying that it can generate a 0.83 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
   Prometheus Biosciences Price Density   
       Price  

Predictive Modules for Prometheus Biosciences

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Prometheus Biosciences. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Prometheus Biosciences' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
199.92199.92199.92
Details
Intrinsic
Valuation
LowRealHigh
150.07150.07219.91
Details
Naive
Forecast
LowNextHigh
190.64190.64190.64
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
191.51196.83202.16
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Prometheus Biosciences. Your research has to be compared to or analyzed against Prometheus Biosciences' peers to derive any actionable benefits. When done correctly, Prometheus Biosciences' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Prometheus Biosciences.

Prometheus Biosciences Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Prometheus Biosciences is not an exception. The market had few large corrections towards the Prometheus Biosciences' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Prometheus Biosciences, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Prometheus Biosciences within the framework of very fundamental risk indicators.
α
Alpha over NYSE Composite
0.83
β
Beta against NYSE Composite2.34
σ
Overall volatility
40.53
Ir
Information ratio 0.11

Prometheus Biosciences Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Prometheus Biosciences for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Prometheus Biosciences can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Prometheus Biosciences is not yet fully synchronised with the market data
Prometheus Biosciences has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 6.81 M. Net Loss for the year was (141.75 M) with loss before overhead, payroll, taxes, and interest of (106.04 M).
Prometheus Biosciences currently holds about 95.96 M in cash with (123.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.35.
Over 81.0% of the company shares are owned by institutional investors

Prometheus Biosciences Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Prometheus Stock often depends not only on the future outlook of the current and potential Prometheus Biosciences' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Prometheus Biosciences' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding40.6 M
Cash And Short Term Investments695.8 M

Prometheus Biosciences Technical Analysis

Prometheus Biosciences' future price can be derived by breaking down and analyzing its technical indicators over time. Prometheus Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Prometheus Biosciences. In general, you should focus on analyzing Prometheus Stock price patterns and their correlations with different microeconomic environments and drivers.

Prometheus Biosciences Predictive Forecast Models

Prometheus Biosciences' time-series forecasting models is one of many Prometheus Biosciences' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Prometheus Biosciences' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about Prometheus Biosciences

Checking the ongoing alerts about Prometheus Biosciences for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Prometheus Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Prometheus Biosciences is not yet fully synchronised with the market data
Prometheus Biosciences has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 6.81 M. Net Loss for the year was (141.75 M) with loss before overhead, payroll, taxes, and interest of (106.04 M).
Prometheus Biosciences currently holds about 95.96 M in cash with (123.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.35.
Over 81.0% of the company shares are owned by institutional investors
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment.
Note that the Prometheus Biosciences information on this page should be used as a complementary analysis to other Prometheus Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.

Other Consideration for investing in Prometheus Stock

If you are still planning to invest in Prometheus Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Prometheus Biosciences' history and understand the potential risks before investing.
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges